At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 206 enrolled
Drug / intervention
CYH33 for tabletdrug
Likely dose
CYH33 for tablet 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.
In Brief
A Phase 1 clinical trial evaluating CYH33 for tablet for Advanced Solid Tumors. Completed, enrolled 206 participants across 30 sites.
Detailed Summary
This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJul 2018
Primary CompletionDec 2024
TodayJul 2026
First PostedJun 4, 2018
Enrollment StartJul 5, 2018
Primary CompletionDec 4, 2024
TodayJul 1, 2026
Enrollment to primary: 6.4 yearsPosted 8.1 years ago
Interventions
CYH33 for tabletdrug
1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)